Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that Forest/AstraZeneca/Dainippon Sumitomo’s Teflaro, which launched in the United States in early 2011 for the treatment of community-acquired pneumonia and complicated skin and skin structure infections (cSSSIs), is poised to find favorable uptake in the hospital setting, particularly among primary care physicians (PCPs). While nearly 70 percent of surveyed hospital pharmacy directors said that Teflaro was not included on their hospital formulary, almost one quarter indicated that their hospital had not yet reviewed Teflaro, suggesting that subsequent formulary inclusion will increase the drug’s patient share in this market. Additionally, surveyed hospital-based PCPs indicate that they are more likely than infectious disease specialists to prescribe Teflaro empirically, and in one year’s time they anticipate prescribing Teflaro to more of their patients across all indications, compared with infectious disease specialists.
The new U.S. Physician & Payer Forum report entitled Gram-Negative Infections: How Will U.S. Payer and Prescriber Receptivity to Novel Antibiotics Shape the Market for These Therapies? also finds that Pfizer’s Zosyn continues to prevail in the treatment of infections due to suspected and confirmed gram-negative pathogens. Surveyed infectious disease specialists and PCPs alike indicate that they frequently use Zosyn empirically to treat suspected gram-negative infections and that they often also employ this agent as a preferred first-line therapy for confirmed gram-negative pathogens. Infectious disease specialists and PCPs both selected Zosyn as their most prescribed and preferred agent for empiric treatment of suspected gram-negative pathogens in hospital-acquired pneumonia. PCPs also frequently prescribe quinolones, such as Janssen’s Levaquin to these patients, while ID specialists prescribe more carbapenems including Merck’s Primaxin.
In patients with microbiologically confirmed infections due to resistant gram-negative pathogens, surveyed infectious disease specialists tend to favor carbapenems for ESBL-producing Enterobacteriaceae and piperacillin/tazobactam-resistant Enterobacteriaceae and they favor Pfizer’s Tygacil or colistin for KPC-producing Enterobacteriaceae. Use of older toxic antibiotics such as colistin and other polymixins in patients with KPC-producing bacteria underscores the limited treatment options in these cases and reveals an important area of unmet need for emerging antibacterials.
The report also finds that Teflaro, Optimer/Cubist/Astellas’s Dificid and Janssen’s Doribax are cited by the highest percentage of surveyed hospital pharmacy directors as not being on formulary, while Tygacil was most frequently selected as being included with restrictions.
“These agents represent the most recently approved antibiotics to treat gram-negative infections and may be subject to formulary exclusions or restricted to approval or step therapy in order to minimize costs,” said Decision Resources Analyst David Holman, Ph.D. “In contrast, older, generically available antibiotics are generally not subject to formulary restrictions.”
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.Business Wire
Last updated on: 10/04/2012